Stoke Therapeutics (STOK) Current Deferred Revenue (2022 - 2026)

Stoke Therapeutics has reported Current Deferred Revenue for 5 years, with the latest figure at $10.1 million in Q1 2026.

• For the quarter ending Q1 2026, Current Deferred Revenue fell 44.58% year-over-year to $10.1 million; the trailing twelve-month figure through Mar 2026 stood at $10.1 million (down 44.58% YoY), and the FY2025 full-year result was $11.9 million, down 37.33% from the prior year.
• Current Deferred Revenue for Q1 2026 stood at $10.1 million, down from $11.9 million in the prior quarter.
• The five-year high for Current Deferred Revenue was $31.6 million in Q3 2024, with the low at $5.8 million in Q3 2025.
• Average Current Deferred Revenue over 5 years is $14.4 million, with a median of $12.8 million recorded in 2022.
• Year-over-year, Current Deferred Revenue soared 261.9% in 2024 and tumbled 81.77% in 2025.
• Tracing STOK's Current Deferred Revenue over 5 years: stood at $14.9 million in 2022, then climbed by 2.88% to $15.3 million in 2023, then climbed by 24.05% to $19.0 million in 2024, then plunged by 37.33% to $11.9 million in 2025, then slipped by 15.42% to $10.1 million in 2026.
• The last three Current Deferred Revenue figures came in at $10.1 million (Q1 2026), $11.9 million (Q4 2025), and $5.8 million (Q3 2025), per Business Quant data.

Peer Comparison